Petal
Executive Summary
Open-source CoScreen/ScreenHero alternative, finally free.
Key Metrics
What is it
Petal is an open-source alternative to collaborative screen-sharing tools like CoScreen and ScreenHero, positioned as "finally free." It surfaced in our tracking under the OpenSource category, first seen on 2026-10-16, with a single mention sourced from Show HN. The pitch is straightforward: the same real-time, multi-user screen collaboration those paid tools offer, without the price tag.
Why now
The signal here is early and thin — just 1 mention across showhn, a score of 59/100, and a nascent stage. That combination means Petal is not yet a trend; it's a data point worth watching. The timing makes sense given that CoScreen and ScreenHero-class tools have long been either paid, discontinued, or absorbed into larger suites, leaving a gap that an open-source project could credibly fill. One Show HN mention is how these things usually start.
Who should care
Indie developers and small SaaS founders who currently pay for or hack around collaborative screen sharing should keep an eye on this. Product people evaluating remote pair-programming or support workflows also fit the profile, since a free open-source option could cut a recurring cost. Given the nascent stage and single mention, treat Petal as a watchlist item rather than a decision — but track it, because open-source alternatives to paid collaboration tools tend to gain momentum fast once they hit Show HN.
Opportunity Analysis
Petal is a very early open-source alternative to CoScreen/ScreenHero with minimal traction (1 Show HN mention). The screen collaboration space is crowded with mature commercial tools, and the free positioning makes monetization difficult. This is a watch-only signal for now—viable only if the project gains real community momentum or you can differentiate on a niche use case.
Want daily opportunity scores like this for every emerging trend?
Start Free Trial →Frequently Asked Questions
What is Petal?
Petal is an open-source alternative to collaborative screen-sharing tools like CoScreen and ScreenHero, positioned as "finally free. " It surfaced in our tracking under the OpenSource category, first seen on 2026-10-16, with a single mention sourced from Show HN. The pitch is straightforward: th...
Why is Petal trending now?
The signal here is early and thin — just 1 mention across showhn, a score of 59/100, and a nascent stage. That combination means Petal is not yet a trend; it's a data point worth watching. The timing makes sense given that CoScreen and ScreenHero-class tools have long been either paid, disconti...
Who should pay attention to Petal?
Indie developers and small SaaS founders who currently pay for or hack around collaborative screen sharing should keep an eye on this. Product people evaluating remote pair-programming or support workflows also fit the profile, since a free open-source option could cut a recurring cost. Given t...
What is the market opportunity for Petal?
The opportunity score for Petal is 38/100. Market demand: 40/100. Competition level: 72/100 (lower is better). Petal is a very early open-source alternative to CoScreen/ScreenHero with minimal traction (1 Show HN mention). The screen collaboration space is crowded with mature commercial tools, and the free positioning makes monetization difficult. This is a watch-only signal for now—viable only if the project gains real community momentum or you can differentiate on a niche use case.
Is Petal worth building right now?
Petal has a revenue potential of ★★ (2/5). Estimated MVP development time: ~45 days. Suggested products: Desktop App, Open Source, Web App, Plugin/Add-on.
Where is Petal being discussed?
Petal has been spotted across 1 independent sources (showhn) with 1 total mentions and 100% growth since 2026-10-16.
Is now the right time to act on Petal?
Petal is in the nascent stage with 100% growth. SEO difficulty is 55/100 (lower is easier to rank). Opportunity score: 38/100.
Don't just track trends — act on them
Every morning, get one actionable product opportunity with evidence, pricing strategy, and validation path. 14-day free trial.
Start Free Trial →